Global /China /Industrials /Specialty Business Services /688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

688192

• SSE: 688192 • Delayed

56.70CNY 2.1%

8.38 USD

As of 6 June 2026, Dizal (Jiangsu) Pharmaceutical Co., Ltd. has a market cap of $3.82B USD, ranking #4604 globally and #942 in China. It ranks #927 in the Industrials sector, and #65 in the Specialty Business Services industry.

Global Rank

4604

Country Rank

942

Sector Rank

927

Industry Rank

Key Stats

Market Cap

$3.82BUSD

25.83B CNY

Enterprise Value

$3.71BUSD

25.14B CNY

Revenue (TTM)

$118.34MUSD

801.14M CNY

EBITDA (TTM)

-$114.71MUSD

-776.5M CNY

Net Income (TTM)

-$112.87MUSD

-764.05M CNY

EBITDA Margin

-97%

Profit Margin

-95%

PS Ratio

32.2

PB Ratio

19.9

Company Profile

Country (HQ)

China

Sector

Industrials

Industry

Specialty Business Services

CEO

Zhang Xiaolin open_in_new

Employees

1,009

Founded

2017

Website

dizalpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.1%	-2.3%	-0.8%	-4.9%	-6%	-3.6%	-3.7%	3.7%	-12%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688192 迪哲(江苏)医药股份有限公司 Class A ISIN: CNE1000055W8 Shares Out.: Shares Outstanding: 465.166M¹ Shares Float: 145.652M² TV: TradingView: SSE: 688192 SA: Stock Analysis: SHA: 688192 YF: Yahoo Finance: 688192.SS GF: Google Finance: SHA: 688192 BA: Barron's: 688192 MS: Morningstar: XSHG: 688192	56.70 CNY	TV: TradingView: SSE: 688192 SA: Stock Analysis: SHA: 688192 YF: Yahoo Finance: 688192.SS GF: Google Finance: SHA: 688192 BA: Barron's: 688192 MS: Morningstar: XSHG: 688192

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shanghai, China.

Similar Companies

Industry: Specialty Business Services (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi XDC Cayman Inc. SHEK: 2268	$9.42B 73.79B HKD 147%	47.0	China
Beijing Compass Technology Development Co., Ltd. SHE: 300803	$8.77B 59.36B CNY 130%	296.1	China
TAL Education Group NYSE: TAL	$6.6B 73%	11.8	China
Hui Lyu Ecological Technology Groups Co.,Ltd. SHE: 001267	$6.25B 42.34B CNY 64%	480.6	China
Jiangsu Boqian New Materials Stock Co., Ltd. SSE: 605376	$4.62B 31.29B CNY 21%	128.4	China
Suzhou Tianmai Thermal Technology Co., Ltd. SHE: 301626	$4.6B 31.16B CNY 21%	163.3	China

Industry: Specialty Business Services (Global)

Name	Market Cap (USD) diff.	PE	Country
Shopify Inc. NASDAQ: SHOP	$158.14B 4K%	129.8	Canada
Verisure plc STO: VSURE	$133.34B 114.8B EUR 3K%	-	United Kingdom
Cintas Corp. NASDAQ: CTAS	$69.6B 2K%	36.8	United States
RELX PLC LSE: REL	$63.91B 47.6B GBP 2K%	23.9	United Kingdom
PayPal Holdings, Inc. NASDAQ: PYPL	$45.83B 1K%	9.4	United States
T Thomson Reuters Corp. NEO: TRI	$41.8B 56.91B CAD 995%	-	Canada

chevron_leftBack